Visualabstract Nivolumab Plus Ipilimumab Improves Recurrence Free NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1 One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within Seven of the 12 patients
Progression Free Survival With Nivolumab Plus Ipilimumab Accordi
Comments are closed.